Becton, Dickinson and Company (BDX) Projected to Release Quarterly Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) will likely be posting its Q4 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of $4.07 per share and revenue of $5.11 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Individuals can check the company’s upcoming Q4 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the firm earned $3.68 EPS. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. On average, analysts expect Becton, Dickinson and Company to post $12.67 EPS for the current fiscal year and $13.24 EPS for the next fiscal year.

Becton, Dickinson and Company Price Performance

BDX stock opened at $194.91 on Thursday. The company’s 50-day moving average price is $186.17 and its two-hundred day moving average price is $170.31. The firm has a market cap of $53.71 billion, a P/E ratio of 58.71, a P/E/G ratio of 13.41 and a beta of 0.21. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $200.47.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. Barclays initiated coverage on shares of Becton, Dickinson and Company in a research note on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective on the stock. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Bank of America boosted their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Finally, Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $185.07.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,907 shares of company stock valued at $1,269,128 over the last ninety days. 0.40% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.